This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: April 4, 2013
Last updated: January 11, 2017
Last verified: January 2017
This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.

Condition Intervention Phase
Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer Biological: AdGMCAIX-transduced autologous dendritic cells Biological: therapeutic autologous dendritic cells Other: laboratory biomarker analysis Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Primary Outcome Measures:
  • Incidence of adverse events including all grade 3 and grade 4 adverse events regardless of causality, treatment-related adverse events, dose limiting toxicities (DLT), and adverse events leading to discontinuation of study treatment [ Time Frame: Up to day 57 ]
    Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03

Secondary Outcome Measures:
  • CAIX-specific immune response [ Time Frame: Up to 3 years ]
    Measured by ELISpot analysis of T cells from blood and cytokine profiling in T cell cultural supernatants.

  • Objective response (CR, PR) according to RECIST guideline version 1.1 [ Time Frame: Up to 3 years ]
  • Duration of progression-free survival [ Time Frame: Up to 3 years ]
  • Clinical benefit rate (CR, PR, and SD) greater than or equal to 12 weeks [ Time Frame: Up to 3 years ]
  • Disease response (CR, PR, stable disease [SD], and progressive disease [PD]) according to RECIST guideline version 1 [ Time Frame: Up to 3 years ]
  • Duration of response according to RECIST guideline version 1 [ Time Frame: Up to 3 years ]
  • Time to disease progression [ Time Frame: Up to 3 years ]

Estimated Enrollment: 18
Study Start Date: December 2012
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (autologous dendritic cells)
Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
Biological: AdGMCAIX-transduced autologous dendritic cells
Given ID
Other Names:
  • dendritic cells transduced with AdGMCA9 expressing GM-CSF-carbonic anhydrase IX fusion protein
Biological: therapeutic autologous dendritic cells
Given ID
Other Names:
  • ADC
  • autologous dendritic cells
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. To determine the safety and tolerability of dendritic cell (DC)-AdGM carbonic anhydrase IX (CAIX) administered by intradermal injections at study doses and schedule.


I. To evaluate clinical antitumor effects following study treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. Parameters include objective response (complete response [CR], partial response [PR]), duration of response in patients with objective response, and time to disease progression.

II. To evaluate immune responses to DC-AdGMCAIX vaccination by enzyme-linked immunospot (ELISpot) for numeric determination of CAIX specific T cells in blood.

III. To evaluate immune responses to DC-AdGMCAIX vaccination by cytokine profiling of T cell culture supernatants for characterization of the immune response in subjects with demonstrated immune activation may be performed.

IV. To evaluate immune responses to DC-AdGMCAIX vaccination by anti-sargramostim (GM-CSF) antibody response.

V. To evaluate tumor biopsies for immune cell infiltrates.

OUTLINE: This is a dose-escalation study.

Patients receive AdGMCAIX-transduced autologous dendritic cells intradermally (ID) on days 1, 15, and 29.

After completion of study treatment, patients are followed up every 2-3 months for at least 6 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed clear cell renal cell carcinoma (ccRCC); pathology report from the original diagnosis of renal cell carcinoma is acceptable; the component of conventional clear cell type > 50% is mandatory
  • Evidence of metastatic disease with measurable lesion(s) as defined by RECIST guideline version 1.1 to permit tumor response evaluation; subjects with unresected primary tumors may be enrolled as long as evidence of measurable metastatic disease is also present
  • Signed informed consent
  • Eastern Cooperative Oncology Group (ECOG) =< 1
  • Expected life expectancy >= 6 months
  • Serum creatinine < 2 mg/dL
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X upper limit of normal (ULN)
  • Total bilirubin < 2 X ULN (except for subjects with documented Gilbert's syndrome who can have total bilirubin < 3.0 mg/dl)
  • Hemoglobin >= 10 g/dL
  • Absolute neutrophil count >= 1.5 X 10^9 cells/L
  • Platelets >= 100 X 10^9/L
  • Having recovered from prior surgery, radiation, chemotherapy (cytotoxic and noncytotoxic) to toxicity grade =< 1 or returned to baseline; previous treatment with immunotherapies, cytotoxic drugs, or other targeted agents is permitted; if cytotoxic chemotherapy was previously received, the last dose must be >= 1 month before leukapheresis; for other agents, the last dose must be >= 14 days before leukapheresis
  • Negative serum pregnancy test within 7 days prior to enrollment in female subjects with reproductive potential

Exclusion Criteria:

  • Rapidly progressing cancer likely to require palliative systemic intervention within 8 weeks after study entry
  • Presence of untreated/active central nervous system (CNS) metastases
  • For subjects with metastatic RCC who have had no prior systemic treatment for RCC and are considered a poor risk according to Motzer criteria, defined by having >= 3 of the following 5 risk factors for short survival: Karnofsky performance score < 80%, lactate dehydrogenase (LDH) > 1.5 X of ULN, hemoglobin < lower limit of normal (LLN), corrected serum calcium > 10 mg/dL (2.5mM), a time from initial diagnosis of RCC to initiation of systemic therapy of < 1 year
  • Non-clear cell or predominantly (> 50%) sarcomatoid histology
  • Concurrent major medical conditions, such as uncontrolled hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, autoimmune disease, adrenal insufficiency, or prior allogeneic organ transplant requiring chronic immunosuppressive therapy, including systemic glucocorticoid treatment or replacement therapy
  • Active or chronic systemic infection, including viral hepatitis, human immunodeficiency virus (HIV), mycobacteria, tuberculosis (TB), or other opportunistic infections
  • Having received systemic immune suppressive therapy within 30 days prior to leukapheresis
  • Having received an investigational agent within 30 days prior to the first dose of study treatment
  • Female subjects who are lactating, pregnant or both male and female subjects with reproductive potential who refuse to practice medically accepted methods for contraception over the period from study consent to 90 days following the last dose of study treatment
  • Other malignancy within 3 years, except for adequately treated non-melanoma skin cancer, non-invasive cancers such as cervical or breast carcinoma in situ, or superficial bladder cancer without local recurrence
  • Social or psychological conditions that the investigator judges may compromise study compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01826877

United States, California
Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Fairooz F. Kabbinavar    888-798-0719   
Principal Investigator: Fairooz F. Kabbinavar         
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Fairooz Kabbinavar Jonsson Comprehensive Cancer Center
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT01826877     History of Changes
Other Study ID Numbers: 12-000577
NCI-2013-00646 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received: April 4, 2013
Last Updated: January 11, 2017

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases processed this record on September 21, 2017